This content is from: Premium Biopharma Deals Offer Hope for Future Public Listings Investors are cautiously optimistic that the sector’s long drought could be coming to an end. By Stephen Taub March 27, 2023
This content is from: Premium There’s New Hope for the IPO Market At least five hedge funds have benefited from two biopharma stocks that went public in February and are currently doing well. By Stephen Taub February 27, 2023
This content is from: Premium RA Capital’s SPAC Merger Bet The biopharma specialist could be signaling renewed confidence in the overall VC market. By Stephen Taub November 28, 2022
This content is from: Premium Another Losing Month for Biopharma Several funds still made big bets on some major holdings. By Stephen Taub April 18, 2023
This content is from: Premium Biopharma Funds Are Still Embracing VC The number of deals is down from last year, but most firms have still been fairly active in the private markets. By Stephen Taub December 21, 2022
This content is from: Premium It’s Been a Bad Year for IPOs — But Hedge Funds Are Betting on These New Offerings Three hedge funds were major investors in a biopharma company that recently went public. By Stephen Taub December 16, 2022
